Summary of Pharming Group 2026 Investor Day Company Overview - **Company**: Pharming Group (NasdaqGM:PHAR) - **Event**: 2026 Investor Day held on February 3, 2026 - **CEO**: Fabrice Chouraqui Financial Performance - **2025 Revenue**: Approximately $376 million, a 27% increase from 2024, slightly exceeding previous guidance [5][6] - **Reconnect Revenue**: $318 million, a growth of 26% year-over-year [7] - **Joenja Revenue**: $58 million, a growth of 29% [7] - **Gross Margin**: Expected around 88%-89% for 2025, excluding a $5 million milestone payment to Novartis [8] - **Cash Position**: $181 million in cash and marketable securities at the end of 2025 [9] 2026 Financial Guidance - **Expected Revenue**: Between $405-$425 million, implying growth of 8%-13% over 2025 [9] - **Reconnect Growth**: Mid-single-digit growth expected, with a decline in ex-U.S. revenues due to market exit [9] - **Joenja Growth**: Anticipated to accelerate, with annual growth around 10 percentage points higher than in 2025 [9] - **Operating Expenses**: Expected between $300 million-$335 million, including over $60 million in R&D investments [10][11] Pipeline and Product Development - **Leniolisib**: Focused on high-prevalence primary immunodeficiencies (PIDs) and is in pivotal phase 2 trials [4][31] - **KL1333 (napazimod)**: Targeting primary mitochondrial disease, also a billion-dollar opportunity [4] - **Joenja**: Committed to pediatric label expansion despite FDA response; Type A meeting scheduled for March [3][10] - **Market Potential**: Both Reconnect and Joenja have over $1 billion sales potential each [2] Market Dynamics - **Reconnect**: Positioned as a cornerstone treatment for difficult-to-treat patients, with a mechanism that provides reliability during crises [2][30] - **Joenja**: Growth opportunities identified in APDS, with potential to reclassify about 250 VUS patients as APDS over time [3] - **CVID Expansion**: Plans to expand into larger PIDs and CVID, unlocking a much larger market [4] Clinical Insights - **Leniolisib's Role**: Investigated for treating immune dysregulation in PIDs, with a strong scientific rationale and patient need [55][56] - **CVID and APDS**: Clinical overlap noted, with a significant portion of CVID patients exhibiting similar characteristics to APDS [44][46] - **Patient Experience**: Anecdotal evidence suggests that leniolisib has provided hope and improved quality of life for patients with CVID [53] Regulatory and Approval Status - **FDA Engagement**: Plans to engage with the FDA regarding pediatric approval for Joenja and address concerns raised in the recent CRL [15][29] - **EMA Approval**: Expected approval for leniolisib in the first half of 2026 [32] Conclusion - Pharming Group is positioned for substantial growth with a strong pipeline and financial performance. The company is focused on expanding its market presence in rare diseases, particularly through innovative treatments like leniolisib and Joenja, while maintaining financial discipline and strategic investments in R&D.